Lupus Research Alliance Thanks FDA for Responsiveness Re Letter Citing Plaquenil Shortages
May 7, 2020
The Lupus Research Alliance held an informative call with the Food and Drug Administration (FDA) in response...
Plaquenil
Lupus Therapeutics, Affiliate of Lupus Research Alliance, Developing a Study Focused on Lupus Patients and COVID-19
New York, NY, April 7, 2020 – Lupus Therapeutics, the clinical trial affiliate of the Lupus Research Alliance (LRA),...
MARCH 26 STATEMENT: Lupus Research Alliance Puts Plaquenil (Hydroxychloroquine) Shortage into Perspective for Lupus Community
March 26, 2020
The Lupus Research Alliance (LRA), the world’s leading research organization dedicated to lupus research, continues to watch...
LRA Sponsors COVID-19 Global Rheumatology Alliance
March 25, 2020
LRA Sponsors COVID-19 Global Rheumatology Alliance
The LRA is proud to be among the sponsors of the COVID-19...
Hydroxychloroquine: Common Lupus Drug in Testing for COVID-19
March 19, 2020
In December 2019, a new virus called SARS-COV-2 was identified in Wuhan, China. This virus was found...
COVID-19 Frequently Asked Questions: What You Should Know
Updated April 3, 2020
The first priority of the Lupus Research Alliance is the health of our lupus community. We...
Potential New Lupus Treatment Outperforms Hydroxychloroquine in Animal Study
November 28, 2018
Anti-malaria drugs such as hydroxychloroquine are common treatments for arthritis and heat rash in patients with lupus....